

Research Project

Phase II Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of H1, an adjuvanted TB subunit vaccine in HIV-infected, BCG-vaccinated Adults With CD4+ Lymphocyte Counts Greater Than 350 Cells/mm3

Third-party funded project

Project title Phase II Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of H1, an adjuvanted TB subunit vaccine in HIV-infected, BCG-vaccinated Adults With CD4+ Lymphocyte Counts Greater Than 350 Cells/mm3

Principal Investigator(s) Reither, Klaus;

Project Members Daubenberger, Claudia ;

Organisation / Research unit

Swiss Tropical and Public Health Institute (Swiss TPH) / Malaria Interventions (Lengeler)

Department

Project start 01.09.2010

Probable end 31.08.2012

Status Completed

Abstract will follow

Financed by

Commission of the European Union

Add publication

Add documents

Specify cooperation partners